By stratifying these by tumour subtype, it was found that 10 women had ER-positive/HER2-negative diseases (three had received chemotherapy), three women had HER2-positive tumours (one received chemotherapy/trastuzumab), and five women had triple-negative tumours (four received chemotherapy). The gene discussed is ERBB2; the disease is neoplasm.